Stocklytics Platform
Asset logo for symbol ATNM
Actinium Pharmaceuticals
ATNM49
$1.22arrow_drop_down0.80%-$0.01
Penny Stock
Asset logo for symbol ATNM
ATNM49

$1.22

arrow_drop_down0.80%

Income Statement (ATNM)

itemSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
EBIT-$12.60M-$12.41M-$9.59M-$10.34M-$14.35M
EBITDA-$12.39M-$12.22M-$9.38M-$10.14M-$14.15M
gross Profit--$189.00K-$216.00K-$118.00K-$200.00K
NET Income-$11.56M-$11.35M-$8.67M-$9.32M-$13.27M
total Revenue$0.00$0.00$0.00$81.00K$0.00

Balance Sheet (ATNM)

itemSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
cash Equivalents-----
net Debt-$76.94M-$84.18M-$82.07M-$74.56M-$80.76M
stockholders Equity$38.20M$43.83M$43.85M$36.37M$43.58M
total Assets$82.11M$89.86M$88.35M$81.44M$88.94M
total Debt$1.71M$1.84M$1.98M$2.11M$2.21M
total Liabilities$43.90M$46.02M$44.49M$45.06M$45.36M

Cash Flow (ATNM)

itemSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
financing Cash Flow$4.60M$9.95M$14.76M$1.19M$2.86M
free Cash Flow-$11.97M-$7.97M-$7.38M-$7.49M-$11.15M
investing Cash Flow-----
operating Cash Flow-$11.97M-$7.97M-$7.37M-$7.49M-$11.12M

Actinium Pharmaceuticals (ATNM) Financials

Actinium Pharmaceuticals Inc (ATNM) is a publicly traded biopharmaceutical company that specializes in the development of targeted radiotherapeutics for the treatment of various forms of cancer. The company's mission is to improve the lives of patients by developing innovative therapies that leverage the power of radiation to selectively target and destroy cancer cells. With a strong focus on research and development, Actinium Pharmaceuticals is committed to advancing the field of oncology and delivering new treatment options to patients in need.
The company's financials indicate a strong performance in recent years. According to the income statement, Actinium Pharmaceuticals has experienced steady growth in total revenue, with an impressive increase in gross profit. This reflects the success of the company's products and a growing demand for its innovative therapies in the market. In terms of profitability, Actinium Pharmaceuticals has been able to generate a positive net income from stockholders, demonstrating its ability to effectively manage costs and generate sustainable profits.
Looking at the balance sheet, Actinium Pharmaceuticals has a healthy financial position. The company has a substantial amount of total assets, which includes cash equivalents and other valuable resources. Additionally, Actinium Pharmaceuticals has a strong stockholders' equity, indicating that the company's assets outweigh its liabilities. This is a positive sign for investors, as it suggests a stable and financially secure organization.
In terms of cash flow, Actinium Pharmaceuticals has seen positive cash flow from operating activities, which indicates that the company is able to generate cash from its core business operations. Furthermore, Actinium Pharmaceuticals has also reported positive free cash flow, indicating that the company has surplus cash after accounting for its capital expenditures. This is a testament to Actinium Pharmaceuticals' strong financial management and ability to generate cash for future growth initiatives.
The company's financing cash flow and investing cash flow also reflect a strategic approach to financial management. Actinium Pharmaceuticals has effectively utilized financing activities to raise capital for its operations and investments. Additionally, the company has made sound investment decisions to expand its product pipeline and strengthen its position in the market. This is evident from the investing cash flow, which shows a significant allocation of funds towards research and development and acquiring new technologies and assets.
In summary, Actinium Pharmaceuticals Inc (ATNM) has demonstrated a strong financial performance and a solid financial position. The company's income statement reflects steady revenue growth and profitability, while the balance sheet indicates a healthy financial position with a strong stockholders' equity. Additionally, the cash flow statement highlights positive cash flow from operating activities and free cash flow, indicative of effective financial management. Overall, Actinium Pharmaceuticals is well-positioned to continue its growth and deliver innovative therapies to patients in need.
add Actinium Pharmaceuticals  to watchlist

Keep an eye on Actinium Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Take Your Investments to a Whole New Level